armonk main associates LLC

542 main street, 2nd floor
new rochelle, new york 10801

NYS Entity Status
ACTIVE

NYS Filing Date
OCTOBER 01, 2013

NYS DOS ID#
4466139

County
WESTCHESTER

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2013 - ARMONK MAIN ASSOCIATES LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • Bio Roundup: Drug Price Debates, NY Bio Blooms & CEOs Take Social Stand
    By Frank Vinluan - Friday Aug 25, 2017

    In these politically divided times, Americans this week found near universal agreement on one thing: A celestial event that plunges a summer day into temporary darkness is a captivating experience. The totality of the solar eclipse lasted less than 3 minutes. If you missed it, you’ll have to wait until 2024 for the next one. […]

    Source: Xconomy VC, Deals, & Startups Feed
  • Listing of the Day: Maine
    Friday Sep 1, 2017

    In 1972, La Rochelle's owners, the Colket family, donated it to The Maine Seacoast Mission. Since then, the house has served as the headquarters for this highly regarded non-profit and has been referred to as the Colket Center.

    Source: The Wall Street Journal: Most Popular
  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy New York
armonk main associates llc new rochelle ny